Medpace (NASDAQ:MEDP) Research Coverage Started at Royal Bank Of Canada

Royal Bank Of Canada began coverage on shares of Medpace (NASDAQ:MEDP) in a research report sent to investors on Tuesday morning, Marketbeat reports. The firm issued an outperform rating and a $522.00 target price on the stock.

Several other equities research analysts have also commented on the stock. Leerink Partners dropped their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 11th. Mizuho set a $582.00 price target on Medpace in a research report on Wednesday, February 11th. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Robert W. Baird upgraded Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective for the company in a research note on Tuesday, February 10th. Finally, Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a report on Friday, February 13th. Five equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $486.67.

Medpace Stock Up 0.8%

NASDAQ MEDP opened at $469.38 on Tuesday. Medpace has a twelve month low of $250.05 and a twelve month high of $628.92. The firm has a market capitalization of $13.32 billion, a PE ratio of 30.68, a P/E/G ratio of 2.23 and a beta of 1.44. The stock’s 50 day moving average is $535.88 and its 200 day moving average is $538.37.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. During the same quarter in the prior year, the company earned $3.67 earnings per share. The firm’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts anticipate that Medpace will post 12.29 earnings per share for the current year.

Institutional Trading of Medpace

Several institutional investors have recently added to or reduced their stakes in the business. Quent Capital LLC purchased a new position in shares of Medpace in the third quarter worth $25,000. Optiver Holding B.V. bought a new stake in Medpace in the 3rd quarter worth about $27,000. Geneos Wealth Management Inc. increased its holdings in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. purchased a new position in Medpace in the 4th quarter worth about $30,000. Finally, Elyxium Wealth LLC bought a new position in Medpace during the 4th quarter valued at about $30,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.